We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




ZyGEM to Commercialize DNA Detection and Testing Platform

By LabMedica International staff writers
Posted on 07 Jun 2010
Print article
ZyGEM Corp. Ltd. (Hamilton, New Zealand; and Solana Beach, CA, USA) has acquired MicroLab Diagnostics Inc., a private company developing microfluidic devices for rapid DNA testing. ZyGEM will market products integrating its DNA extraction, reagents, and detection assays with microfluidic chip technology developed by MicroLab, which will operate as a business unit of the new company.

MicroLab's miniaturization of the entire DNA testing process within a single closed system significantly reduces the amount of sample and reagents that are needed, while virtually eliminating the chances for handling error or contamination. The integrated new products will dramatically decrease the time, complexity, and cost of conducting DNA testing and have transformational potential in a broad range of applications.

The ZyGEM/MicroLab system is compact, easy-to-use, and cost-effective, making it suitable for use both in the laboratory and out in the field. It can perform multiplexed analyses, and it can also be configured for specific applications. Portable handheld versions are in development.

A prototype of the new system produced accurate DNA results in less than an hour, comparable to results obtained with current technology requiring three separate instruments and 5 to 10 hours. The new technology has the potential for applications where accuracy, speed, and ease-of-use are critical, including, point-of-care diagnostics, forensics, biodefense, and food pathogen testing.

ZyGEM intends to continue to expand sales of its proprietary assays and kits that use a thermophilic enzyme to extract DNA or RNA from a wide range of sample types using a single, closed-tube system.

Under the terms of the agreement, the new company will be called ZyGEM and will be headquartered in Charlottesville, Virginia (USA).

Dr. James Landers, cofounder of MicroLab Diagnostics and CSO of the new company, noted, "ZyGEM brings us DNA extraction and detection technology that is an ideal fit with our microchips, enabling us to achieve a seamless sample-to-answer solution with broad market applicability. It also brings us commercial expertise and a global network of distributors and partners.

Related Links:

ZyGEM Corp. Ltd.
MicroLab Diagnostics Inc.


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.